Clinical Trials
Research Studies
ACNS1422: A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
ACNS1831: A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 Associated Low-Grade Glioma
ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib in Newly Diagnosed or Previously Untreated Low-Grade Glioma not associated with BRAFV600E Mutations or Systemic (NF1)
ACNS2021: A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular & Spinal Canal Irradiation for Patients with Localized Non-Germinomatous CNS Germ Cell Tumor
AGCT1532: A Randomized Phase 3 Trial of Accelerated versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumors.
AALL1631: International Phase 3 Trial in Philadelphia. Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
AALL1731: A Phase 3 Trial Investigating Blinatumomab in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-ALL and the Treatment of Patients with Localized B-LLy
AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy
AALL1821: A Phase 2 Study of Blinatumomab in Combination with Nivolumab, a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse
AAML1831: A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO, and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations
AAML1921: A Phase 1/2 Study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia
AAML18P1: Stopping Tyrosine Kinase Inhibitors to Assess Treatment-Free Remission in Pediatric Chronic Myeloid Leukemia - Chronic Phase
AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy
ANHL1931: A Randomized Phase 3 trial of Nivolumab in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
APEC1621 A: Phase 2 subprotocol of LOXO-101 in patients with tumors harboring actionable NTRK fusions
APEC1621 F: Phase 2 subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations
APEC1621 K: Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients with Tumors Harboring IDH1 Mutations
APEC1621 M: Phase 2 Subprotocol of Tipifarnib in patients with tumors harboring HRAS genomic alterations
APEC1621 N: Phase 2 Subprotocol of LOXO-292 in Patients with Tumors Harboring RET Gene Alterations
ANBL1531: A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma.
ANBL1821: A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) in Children with Relapsed, Refractory or Progressive Neuroblastoma.
APAL2020SC: Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
APEC14B1: Project: EveryChild A Registry, Eligibility Screening, Biology and Outcome Study
AREN03B2: Renal Tumors Classification, Biology, and Banking Study
ALTE05N1: Umbrella Long-term Follow-up Protocol
ALTE07C1: Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer
ALTE2031: StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors